Skip to content

Comparison of the Efficacy and Safety of Insulated vs. Non-Insulated Gold Microneedle Radiofrequency in the Treatment of Atrophic Acne Scars: A Prospective, Randomized, Split-Face Controlled Trial

Comparison of the Efficacy and Safety of Insulated vs. Non-Insulated Gold Microneedle Radiofrequency in the Treatment of Atrophic Acne Scars: A Prospective, Randomized, Split-Face Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106896
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne scars

Interventions

Group I:Treated with non-insulated gold microneedle radiofrequency
Group II:Treated with insulated gold microneedle radiofrequency

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 Bilateral presentation of comparable atrophic acne scars 2 Age >= 18 years 3 Willingness to comply with follow-up visits and study protocol

Exclusion criteria

Exclusion criteria: 1 Patients with acute allergic reactions, open wounds, or active skin infections in the treatment area. 2 Individuals with underlying dermatological conditions (e.g., facial dermatitis, psoriasis). 3 Poorly controlled inflammatory acne. 4 History of keloids or keloid predisposition. 5 Patients with severe systemic diseases, malignancies, immunodeficiency disorders, psychological disorders, or mental illnesses. 6 Photosensitivity or use of photosensitizing medications (e.g., diuretics, antibiotics including doxycycline or tetracyclines). 7 Receipt of any energy-based facial treatments within the past 3 months. 8 Pregnancy or lactation. 9 Poor compliance (inability to adhere to scheduled treatments or refrain from alternative therapies during the study period).

Design outcomes

Primary

MeasureTime frame
Clinical ECCA Grading by Physicians;Clinical Investigator's Global Assessment (IGA) of Treatment Efficacy;VISIA? Skin Analysis System;Skin Function Analyzer;

Secondary

MeasureTime frame
Patient Satisfaction Assessment;dermatology life quality index;Immediate postoperative adverse reactions;

Countries

China

Contacts

Public ContactJianwen Ren

The Second Affiliated Hospital of Xi'an Jiaotong University

rjwqqq2005@126.com+86 153 9906 3903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026